Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129689

Targeting CD137 enhances the efficacy of cetuximab

Holbrook E Kohrt, A Dimitrios Colevas, Roch Houot, Kipp Weiskopf, Matthew J Goldstein, Peder Lund, Antonia Mueller, Idit Sagiv-Barfi, Aurelien Marabelle, Ruth Lira, Emily Troutner, Lori Richards, Amanda Rajapaska, Jonathan Hebb, Cariad Chester, Erin Waller, Anton Ostashko, Wen-Kai Weng, Lieping Chen, Debra Czerwinski, Yang-Xin Fu, John Sunwoo, Ronald Levy
PMCID: PMC6546445  PMID: 31157621

Original citation: J Clin Invest. 2014;124(6):2668–2682. https://doi.org/10.1172/JCI73014

Citation for this retraction: J Clin Invest. 2019;129(6):2595. https://doi.org/10.1172/JCI129689

Stanford University School of Medicine recently notified the JCI of concerns regarding Figure 4, B, C, and E, Figure 5, B, D, and F, and Figure 6B and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the JCI is retracting this article.

Version 1. 06/03/2019

Print issue publication

Footnotes

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES